13F Portfolios

Caledonia (Private) Investments Pty Ltd — ROYALTY PHARMA PLC RPRX: Quarterly 13F Position History

Caledonia (Private) Investments Pty Ltd has reported ROYALTY PHARMA PLC (RPRX) on 5 13F-HR filings in Pactolio's tracked window, first appearing in Q1 2025. As of Q1 2026, the position is sized at 7,168,399 shares ($343.9M market value, 10.00% of the equity book). Quarter-over-quarter share count change: 208,639 (-2.8%) .

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 5 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q1 2026 7,168,399 208,639 -2.8% $343.9M 10.00% $47.97
Q4 2025 7,377,038 170,571 -2.3% $285.0M 5.46% $38.64
Q3 2025 7,547,609 +1,102,880 +17.1% $266.3M 4.33% $35.28
Q2 2025 6,444,729 +1,330,162 +26.0% $232.2M 3.69% $36.03
Q1 2025 5,114,567 $159.2M 2.59% $31.13

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.

When did Caledonia (Private) Investments Pty Ltd first disclose a RPRX position in 13F-HR filings?

Caledonia (Private) Investments Pty Ltd first reported ROYALTY PHARMA PLC (RPRX) on its 13F-HR filing for the period ending 2025-03-31 (Q1 2025). The position has appeared on 5 reported quarters within Pactolio's tracked window.

What was Caledonia (Private) Investments Pty Ltd's most recent quarter-over-quarter share-count change in RPRX?

Between Q4 2025 and Q1 2026, Caledonia (Private) Investments Pty Ltd reduced its RPRX position by 208,639 shares (-2.8%), leaving 7,168,399 shares at a market value of $343.9M.

Does the implied price-per-share represent Caledonia (Private) Investments Pty Ltd's cost basis in RPRX?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.